Compare Dicks Sporting Goods Inc (DKS) vs TG Therapeutics Inc (TGTX) Price & Performance

Dick's Sporting Goods (DKS) trades at $216.10, down 0.86% with a bearish technical outlook despite strong fundamentals. The company reported consistent earnings beats, with Q1 2026 EPS of $2.90 exceeding expectations, and maintains solid profitability with a 4.71% net margin. Recent developments include the launch of ScoreCard+ loyalty program and Lids partnership expansion. Analyst consensus remains strongly bullish with a $261 price target, though legal scrutiny over fiduciary duties presents near-term headwinds.

DKS offers attractive valuation with a P/E of 20.58 and P/S of 0.96, trading below analyst targets. Growth catalysts include market share gains and strategic partnerships, but risks involve competitive pressures and potential legal overhangs. The stock's current dip may present a buying opportunity for long-term investors given fundamental strength and institutional support.

TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.

Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.